Infosys Limited vs Eli Lilly And Co — how do they compare? Infosys Limited trades at $12.4 (market cap $50.32B), while Eli Lilly And Co trades at $1,215 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 21.9× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.17%). Which is the better fit depends on your goals.
| INFY | LLY | |
|---|---|---|
Market Cap | $50.32B | $1.10T |
Sector | Technology | Health |
52-Week High | $20.22 | $1.24K |
52-Week Low | $10.49 | $639.43 |
Enterprise Value | $48.07B | $1.14T |
Dividend Yield | 4.17% | 0.56% |
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.
The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →